- Home
- LNC vs LEGN Comparison
LNC vs LEGN Comparison
Compare LNC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNC | LEGN |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LNC | LEGN |
|---|---|---|
| Price | $42.29 | $17.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $43.13 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.65 | N/A |
| Revenue | ★ $18,212,000,000.00 | N/A |
| Revenue This Year | $9.60 | $42.68 |
| Revenue Next Year | $3.73 | $30.52 |
| P/E Ratio | $7.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.18 | $16.24 |
| 52 Week High | $47.67 | $37.50 |
Technical Indicators
Market Signals| Indicator | LNC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 33.03 |
| Support Level | $41.93 | $16.47 |
| Resistance Level | $46.74 | $21.99 |
| Average True Range (ATR) | 1.14 | 0.89 |
| MACD | -0.15 | -0.31 |
| Stochastic Oscillator | 30.63 | 11.95 |
Price Performance
Historical ComparisonAbout LNC Lincoln National Corporation
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability, and dental.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.